Drug delivery to vitreous in comparison with drug delivery to the other parts of the eye is complicated and challenging due to the existence of various anatomical and physiological barriers. Developing injectable intra-vitreal implant could be beneficial in this regard. Herein, poly(hydroxybutyrate-co-valerate) (PHBV) implants were fabricated and optimized using response surface method for budesonide (BZ) delivery. The acquired implants were characterized in regard to the stability of the ingredients during fabrication process, drug loading amount, and drug release pattern (in PBS-HA-A and in vitreous medium). According to this research and statistical analysis performed, first HV% (hydroxyvalerate) then molecular weight and ratio of PEG as pore former affect respectively release rate and burst strength of BZ with different coefficients. Drug release profile in rabbit eye correlated well with that of in vitro (R² = 0.9861, p ˂ 0.0001). No significant changes were seen in ERG waves, intraocular pressure, and histological studies during the in vivo part of the project. Using 8% HV, 20% PEG/PHBV, and higher molecular weight PEG (i.e., 6000), the optimum formulation was achieved. Toxicity and biocompatibility of the optimized formulation, which were evaluated in vivo, indicated the suitability of design implant for intra-vitreal BZ delivery.

由于存在各种解剖学和生理学障碍，与向眼睛其他部位的药物输送相比，向玻璃体的药物输送是复杂且具有挑战性的。在这方面，开发可注射的玻璃体内植入物可能是有益的。在这里，聚（羟基丁酸-共-戊酸酯）（PHBV）植入物被制作和使用响应面法优化布地奈德（BZ）交付。获得的植入物的特征在于制造过程中成分的稳定性，载药量和药物释放方式（在PBS-HA-A和玻璃介质中）。根据这项研究和进行的统计分析，首先是HV％（羟基戊酸），而分子量和作为成孔剂的PEG的比例分别影响BZ的释放速率和爆破强度，而系数不同。体外（R ²  ＝ 0.9861，p  ＜0.0001）。在项目的体内部分，ERG波，眼压和组织学研究均未见明显变化。使用8％HV，20％PEG / PHBV和更高分子量的PEG（即6000），可获得最佳配方。体内评估的优化配方的毒性和生物相容性表明设计植入物适合玻璃体内BZ递送。